Stock Taper 
ODTX
$24.36
▼ DOWN 6.24% (-1.62)
KEY STATISTICS
Market Cap$1.17 B
52w High$28.00
52w Low$15.10
Dividend Yield—
Frequency—
P/E-3.61
Volume117.28K
Shares Out.48.03M
COMPANY
LEADERSHIP
CHIEF EXECUTIVE
Gary D. Glick
ABOUT
SECTOR
Healthcare
WENT PUBLIC
May 8, 2026
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
100
PRICE TARGET
Target High$44.00
Target Low$30.00
Target Median$40.00
Target Consensus$38.00
UPCOMING EARNINGS
DateNov 4, 2026
DayWednesday
Rev. Est.—
NOV
4
WED
PRICE
$24.36 ▼ DOWN 6.24% (−$1.62)About Odyssey Therapeutics, Inc.
https://odysseytx.com ↗Odyssey Therapeutics, Inc. is a Boston-based clinical-stage biopharma developing innovative treatments for autoimmune and inflammatory diseases, with a pipeline including small molecule inhibitors and protein therapeutics targeting IRF5, TLRs, Tre...
INDUSTRY
Biotechnology
A PRODUCT ODYSSEY THERAPEUTICS, INC. IS KNOWN FOR
OD-001
OD-001, Odyssey Therapeutics' lead Phase 2 oral RIPK2 inhibitor, targets inflammatory bowel disease, specifically ulcerative colitis, as a novel therapy for autoimmune and inflammatory conditions.
ETFS HOLDING THIS STOCK
ETFS HOLDING
17
LISTED HERE
2
RANKED BY POSITION SIZE
INSTITUTIONAL OWNERSHIP
SHARES OWNED
52.14%
HOLDERS
50
TOP 12 OF 50 · RANKED BY POSITION SIZE
Fmr LLC
Sr One Capital Management, LP
Tpg Gp A, LLC
Lightspeed Management Company, L.L.C.
Orbimed Advisors LLC
Deerfield Management Company, L.P. (Series C)
Sands Capital Ventures, LLC
Hhlr Advisors, Ltd.
General Catalyst Group Management, LLC
Affinity Asset Advisors, LLC
Adage Capital Partners Gp, L.L.C.
Foresite Capital Management V, LLC
RATINGS SNAPSHOT
Overall rating: C
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity3
Price To Earnings1
Price To Book4
Overall Score2
MOST RECENT ANALYST GRADES
GRADE SUMMARY
OVERWEIGHT 1
OUTPERFORM 1
2 GRADES IN THE LAST 12 MONTHS
